drugset / Trial / NCT00648219

Fed Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg

NCT00648219

Phase 1 Completed 36 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan's olmesartan medoxomil 40 mg tablets to Sankyo's Benicar® 40 mg tablets following a single, oral 40 mg (1 x 40 mg) dose administered under fed conditions.

Timeline

Start
2005-12
Primary completion
2005-12
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Olmesartan medoxomil Unknown 40 mg Oral

Indications

No indication recorded.